Press Releases

Provention Bio to Present at the 2019 Cantor Global Healthcare Conference

OLDWICK, N.J., Sept. 25, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019, at 4:45 pm E.T. The conference is being held at the InterContinental New York Barclay Hotel, New York, NY.

(PRNewsfoto/Provention Bio, Inc.)

The presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Provention Bio, Inc.

Provention Bio, Inc. (Nasdaq: PRVB) is a clinical-stage biopharmaceutical company leveraging a transformational drug development strategy that is focused on the prevention or interception of immune-mediated disease. Provention's mission is to in-license, transform and develop therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases including: type 1 diabetes (T1D), Crohn's disease, celiac disease and lupus. Provention's diversified portfolio includes advanced-stage product development candidates that have undergone clinical testing by other companies.

Sam Martin, Argot Partners 

David Rosen

Cision View original content to download multimedia:

SOURCE Provention Bio, Inc.